N/A
N=727
Motivational Interviewing (MI) Intervention to Improve Adherence
Diabetes Mellitus, Type 2 · Hypertension
Bottom Line
View on ClinicalTrials.gov: NCT03985098 ↗Enrolled (actual)
727
Serious AEs
0.0%
Results posted
Jun 2023
Primary outcome: Primary: Adherence Measure — 0.63; 0.56 Proportion of days covered
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Motivational interviewing intervention arm (Behavioral)
- Age
- Older Adult · 65+ yrs
- Sex
- All
- Sponsor
- University of Houston
- Primary completion
- Mar 2021
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Adherence Measure |
0.63; 0.56 | — |
Summary
The purpose of this study is to examine the effectiveness of a telephone motivational interviewing intervention by pharmacy students in enhancing adherence to angiotensin converting enzyme inhibitors (ACEI)/ angiotensin receptor blockers (ARB) (ACE/ARBs) among patients with diabetes and hypertension in a Medicare advantage plan.
Eligibility Criteria
Inclusion Criteria
- Continuous enrollment over the study period July 2016 to December 2018.
- A prescription filled for an ACEI or ARB medication between July 1st, 2017- December 31st, 2017. This will be defined as the index date (for phase 1).
- Diagnosis of both DM and HTN prior to index date, identified through the health plan's medical claims program (CCMS) using the International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) codes only.
Exclusion Criteria
- Disenrollment from drug plan.
- Death prior to end of the study.
- Having a diagnosis of dementia in the one-year pre-index period.
- Having an ACEI/ARB contraindication like angioedema, hyperkalemia, and renal artery stenosis in the one-year pre-index period.
Data sourced from ClinicalTrials.gov (NCT03985098). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.